Abstract
The anticarcinogenic and antioxidant properties of vitamins A, C, E and pro- or antioxidant properties of trace metals have recently attracted increased attention. We examined the levels of antioxidant vitamins (A, C and E), selenium and malondialdehyde (MDA), and trace metals (Fe, Ni, Zn, Co and Cu) in patients with prostate cancer. In total, 41 subjects (21 controls and 20 prostate cancer patients) were included in the study. The levels of trace elements and Fe in whole blood were determined by atomic absorption spectrophotometry. Serum levels of Se were determined using a fluorimetric method, while a HPLC method was used for serum levels of vitamins and MDA. The levels of vitamins A and E were significantly lower and MDA levels were significantly higher (p<0.001) in patients with prostate cancer compared to controls. Serum vitamin C was significantly lower in patients with prostate cancer when compared to controls (p<0.01). Moreover, Se and Zn levels were also significantly lower, and levels of Ni, Co, and Cu were higher (p<0.001) in patients with prostate cancer than in controls. Fe levels were not significantly different in patients compared to controls (p>0.05). Our findings, together with the results of previous animal studies, suggest that the administration of vitamins A, C, and E, and Se and Zn may be beneficial in the prevention and treatment of human prostate cancer.
References
1. Templar J, Kon SP, Milligan TP, Newman DJ, Raftery MJ. Increased plasma malondialdehyde levels in glomerular disease as determined by a fully validated HPLC method. Nephrol Dial Transpl 1999; 14:946–51.10.1093/ndt/14.4.946Search in Google Scholar
2. Das U. A radical approach to cancer. Med Sci Monit 2002; 8:79–92.Search in Google Scholar
3. Halliwell B. Effect of diet on cancer development: is oxidative DNA damage a biomarker? Free Radic Biol Med 2002; 15:968–74.10.1016/S0891-5849(02)00808-0Search in Google Scholar
4. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33:1075–107.10.1016/S0959-8049(96)00492-3Search in Google Scholar
5. Babbs CF. Free radicals and etiology of colon cancer. Free Radic Biol Med 1990; 8:191–201.10.1016/0891-5849(90)90091-VSearch in Google Scholar
6. Moon RC, McCormick DL, Mehta RG. Inhibition of carcinogenesis by retinoids. Cancer Res 1983; 43:2469–75.Search in Google Scholar
7. Halliwell B. Free radical antioxidants in human disease. Curiosity, cause or consequence? Lancet 1994; 344:72–4.Search in Google Scholar
8. Kolonel LN, Hinds MW, Nomura AM, Hankin JH, Lee J. Relationship of dietary vitamin A and ascorbic acid intake to the risk for cancers of the lung, bladder and prostate in Hawaii. Natl Cancer Inst Monogr 1985; 69:137–42.Search in Google Scholar
9. Tehophanides T, Anastassopoulou J. Copper and carcinogenesis. Crit Rev Oncol Hematol 2002; 42:57–64.10.1016/S1040-8428(02)00007-0Search in Google Scholar
10. Bray TM, Better WJ. The physiological role of zinc as an antioxidant. Free Radic Biol Med 1990; 8:281–91.10.1016/0891-5849(90)90076-USearch in Google Scholar
11. Gouget B, Sergeant C, Llabador Y, Deves G, Vesvres MH, Simonoff M. Trace metals and cancer: the case of neuroblastoma. Nucl Instrum Methods B 2001; 181:465–9.10.1016/S0168-583X(01)00469-4Search in Google Scholar
12. Desoize B. Cancer and metals and metal compounds: part I – carcinogenesis. Crit Rev Oncol Hematol 2002; 42:1–3.10.1016/S1040-8428(02)00017-3Search in Google Scholar
13. Miller KW, Lorr NA, Yang CS. Simultaneous determination of plasma retinol, α-tocopherol, lycopene, α-carotene, and β-carotene by high performance liquid chromatography. Anal Biochem 1984; 138:340–5.10.1016/0003-2697(84)90819-4Search in Google Scholar
14. Cerhata D, Bauerova A, Ginter B. Determination of ascorbic acid in serum using high performance liquid chromatography and its correlation with spectrophotometric (colorimetric) determination. Ceska Slov Farm 1994; 43:166–70.Search in Google Scholar
15. Tavazzi B, Lazzarino G, Di-Piero D, Giardina B. Malondialdehyde production and ascorbate decrease are associated to the reperfusion of the isolated postischemic rat heart. Free Radic Biol Med 1992; 13:75–8.10.1016/0891-5849(92)90167-FSearch in Google Scholar
16. Karatas F, Karatepe M, Baysar A. Determination of free malondialdehyde in human serum by high performance liquid chromatography. Anal Biochem 2002; 311:76–9.10.1016/S0003-2697(02)00387-1Search in Google Scholar
17. Whetter PA, Ullrey DE. Improved fluorometric method for determining selenium. J Assoc Anal Chem 1978; 61:927–30.Search in Google Scholar
18. Goodman GE, Schaffer S, Omenn GS, Chen C, King I. The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev 2003; 12:518–26.Search in Google Scholar
19. Reichman ME, Hayes RB, Ziegler RG, Schatzkin A, Taylor PR, Kahle LL, et al. Serum vitamin A and subsequent development of prostate cancer in the first National Health and Nutrition Examination Survey epidemiologic follow-up study. Cancer Res 1990; 50:2311–5.Search in Google Scholar
20. Hayes RB, Bogdanovicz JF, Schroeder FH, De Bruijn A, Raatgever JW, Van der Maas PJ, et al. Serum retinol and prostate cancer. Cancer 1988; 62:2021–6.10.1002/1097-0142(19881101)62:9<2021::AID-CNCR2820620925>3.0.CO;2-RSearch in Google Scholar
21. Shibata A, Paganini-Hill A, Ross RK, Henderson BE. Intake of vegetables, fruits, beta-carotene, vitamin C and vitamin supplements and cancer incidence among the elderly: a prospective study. Br J Cancer 1992; 66:673–9.10.1038/bjc.1992.336Search in Google Scholar
22. Benedict WF, Jones PA. Inhibition of transformation and oncogenic progression by ascorbic acid: a possible role in chemoprevention. In: Arnot MS, van Eys J, Wang YM, editors. Molecular interrelations of nutrition and cancer. New York: Raven Press, 1982:351–7.Search in Google Scholar
23. Yalcin O, Karatas F, Erulas FA, Özdemir E. The levels of glutathione peroxidase, vitamin A, E, C and lipid peroxidation in patients with transitional cell carcinoma of the bladder. BJU Int 2004; 93:863–6.10.1111/j.1464-410X.2003.04729.xSearch in Google Scholar
24. Suhr D, Brummer F, Irmer U, Schlachter M, Hulser DF. Reduced cavitation-induced cellular damage by the antioxidative effect of vitamin E. Ultrasonics 1994; 32:301–7.10.1016/0041-624X(94)90010-8Search in Google Scholar
25. Al-Saleh IA, Al-Doush I. Selenium levels in wheat grains grown in Saudi Arabia. Bull Environ Contam Toxicol 1997; 59:590–4.10.1007/s001289900520Search in Google Scholar
26. Willett WC, Polk BF, Morris JS, Stampfer MJ, Pressel S, Rosner B, et al. Prediagnostic serum selenium and risk of cancer. Lancet 1983; 2:130–4.10.1016/S0140-6736(83)90116-2Search in Google Scholar
27. Barrington JW, Jones A, James D, Smith S, Stephenson TP. Antioxidant deficiency following clam enterocystoplasty. Brit J Urol 1997; 80:238–42.10.1046/j.1464-410X.1997.00250.xSearch in Google Scholar
28. Meuillet E, Stratton S, Prasad Cherukuri D, Goulet AC, Kagey J, Porterfield B, et al. Chemoprevention of prostate cancer with selenium: an update on current clinical trials and preclinical findings. J Cell Biochem 2004; 91:443–58.10.1002/jcb.10728Search in Google Scholar
29. Gonenc A, Ozkan Y, Torun M, Simsek B. Plasma malondialdehyde (MDA) levels in breast and lung cancer patients. J Clin Pharm Ther 2001; 26:141–4.10.1046/j.1365-2710.2001.00334.xSearch in Google Scholar
30. Siddiqui MK, Srivastava S, Mehrotra PK. Environmental exposure to lead as a risk for prostate cancer. Biomed Environ Sci 2002; 15:298–305.Search in Google Scholar
31. Biri H, Cimen MY, Kacmaz M, Buyukkocak S, Sen I, Ozturk HS, et al. Antioxidant potential of cancerous human kidney tissues. Cancer Biochem Biophys 1998; 16:265–72.Search in Google Scholar
32. Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willett WC, Giovannucci EL. Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 2003; 95:1004–7.10.1093/jnci/95.13.1004Search in Google Scholar
33. Coates RJ, Weiss NS, Daling JR, Rettmer RL, Warnick GR. Cancer risk in relation to serum copper levels. Cancer Res 1989; 49:4353–6.Search in Google Scholar
34. Ma EL, Jiang ZM. Ion-exchange chromatography in simultaneous determination of serum copper and zinc levels in patients with cancer of digestive tract. Chin Med J Peking 1993; 106:118–21.Search in Google Scholar
35. Picurelli L, Olcina PV, Roig MD, Guntherner S, Ferrer J. Determination and relationship of the copper and zinc concentrations in normal and pathological prostatic tissue. Trace Elem Med 1991; 8:131–7.Search in Google Scholar
36. Picurelli L, Olcina PV, Roig MD, Guntherner S, Ferrer J. Determination and relationship of the iron and magnesium concentrations in normal and pathological prostatic tissue. Trace Elem Med 1992; 9:14–9.Search in Google Scholar
37. Faroon OM, Williams M, O'Connor R. A review of the carcinogenicity of chemicals most frequently found at national priorities list sites. Toxicol Ind Health 1994; 10:203–30.10.1177/074823379401000309Search in Google Scholar
38. Hall IH, Lackey CB, Kistler TD, Durham RW Jr, Russell JM, Grimes RN. Antitumor activity of mono- and dimetallic transition metal carborane complexes of Ta, Fe, Co, Mo, or W. Anticancer Res 2000; 20:2345–54.Search in Google Scholar
39. Mitchell CR, Folkard M, Joiner MC. Effects of exposure to low-dose-rate (60)Co gamma rays on human tumor cells in vitro. Radiat Res 2002; 158:311–8.10.1667/0033-7587(2002)158[0311:EOETLD]2.0.CO;2Search in Google Scholar
40. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem 2005; 12:1161–208.10.2174/0929867053764635Search in Google Scholar
©2006 by Walter de Gruyter Berlin New York
